Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases

Molecular Pharmacology

Volumn 67, Issue 4, 2005, Pages 1369-1381

  Beeton, Christine ^a   Pennington, Michael W ^b   Wulff, Heike ^c   Singh, Satendra ^b   Nugent, Daniel ^b   Crossley, George ^b   Khaytin, Ilya ^b   Calabresi, Peter A ^d   Chen, Chao Yin ^c   Gutman, George A ^a   Chandy, K George ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Bachem Holding AG   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 1,4 DIHYDRO 4 PENTYLIMINOQUINOLINE; 1 BENZYL 7 CHLORO 4 N PROPYLIMINO 1,4 DIHYDROQUINOLINE; 4 [(DIPHENYLMETHOXY)METHYL] 1 [3 (4 METHOXYPHENYL)PROPYL]PIPERIDINE; 4 BENZHYDRYLOXYMETHYL 1 [3 (4 METHOXYPHENYL)PROPYL]PIPERIDINE; KALIOTOXIN; MARGATOXIN; PIPERIDINE DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.3; QUINOLINE DERIVATIVE; SEA ANEMONE TOXIN; STICHODACTYLA HELIANTHUS TOXIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; WIN 17317;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CARDIOTOXICITY; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; EFFECTOR CELL; ELECTROCARDIOGRAM; HUMAN; HUMAN CELL; LYMPHOID CELL; MEMORY CELL; MULTIPLE SCLEROSIS; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; CELL LINE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; KV1.1 POTASSIUM CHANNEL; KV1.3 POTASSIUM CHANNEL; LYMPHOCYTE ACTIVATION; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED; RATS; RATS, INBRED LEW; T-LYMPHOCYTES;

EID: 20144366005     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.008193     Document Type: Article

References (68)

1. Atwal KS, Vaccaro W, Lloyd J, Finlay H, Yan L, and Bhandaru RS (2001) inventors, Bristol-Myers Squibb, assignee. Heterocyclic dihydropyrimidines as potassium channel inhibitors. World patent WO0140231. 2001 Jun 7.
2. Baell JB, Gable RW, Harvey AJ, Toovey N, Herzog T, Hansel W, and Wulff H (2004) Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. J Med Chem 47:2326-2336.
3. Bagdány M, Batista CVF, Valdez-Cruz NA, Somodi S, Rodriguez de la Vega RC, Licea AF, Gáspár R, Possani LD, and Panyi G (2005) Anuroctoxin, a new scorpion toxin of the α-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes. Mol Pharmacol 67:1-11.
4. Bao J, Miao S, Kayser F, Kotliar AJ, Baker RK, Doss GA, Felix JP, Bugianesi RM, Slaughter RS, and Kaczorowski GJ (2005) Potent Kv1.3 inhibitors from correolide-modification of the C18 position. Bioorg Med Chem Lett 15:447-451.
5. Bardien-Kruger S, Wulff H, Arieff Z, Brink P, Chandy KG, and Corfield V (2002) Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders and its exclusion as cause of progressive familial heart block I (PFHBI). Eur J Hum Genet 10:36-43.
6. + channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol 166:936-944.
7. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 98:13942-13947.
8. Beeton C, Wulff H, Singh S, Botsko S, Crossley G, Gutman GA, Cahalan MD, Pennington MW, and Chandy KG (2003) A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. J Biol Chem 278:9928-9937.
9. Beraud E, Balzano C, Zamora AJ, Varriale S, Bernard D, and Ben-Nun A (1993) Pathogenic and non-pathogenic T lymphocytes specific for the encephalitogenic epitope of myelin basic protein: functional characteristics and vaccination properties. J Neuroimmunol 47:41-53.
10. Bunce C and Bell EB (1997) CD45RC isoforms define two types of CD4 memory T cells, one of which depends on persisting antigen. J Exp Med 185:767-776.
11. Butenschon I, Moller K, and Hansel W (2001) Angular methoxy-substituted furo- and pyranoquinolinones as blockers of the voltage-gated potassium channel Kv1.3. J Med Chem 44:1249-1256.
12. Castle NA, Hollinshead SP, Hughes PF, Mendoza GS, Searafin J, Wilson JW, Amato GS, Beaudoin S, Gross M, and McNaughton-Smith G (2000) inventors, ICAgen and Eli Lilly & Company, assignee. Potassium channel inhibitors. U.S. patent 6,083,986. 2000 Jul 4.
13. Chandy KG, DeCoursey TE, Cahalan MD, McLaughlin C, and Gupta S (1984) Voltage-gated potassium channels are required for human T lymphocyte activation. J Exp Med 160:369-385.
14. + channels as targets for specific immunomodulation. Trends Pharmacol Sci 25:280-289.
15. Corcione A, Casazza S, Ferretti E, Giunti D, Zappia E, Pistorio A, Gambini C, Mancardi GL, Uccelli A, and Pistoria V (2004) Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci USA 101:11064-11069.
16. Cotton J, Crest M, Bouet F, Alessandri N, Gola M, Forest E, Karlsson E, Castaneda O, Harvey AL, Vita C, et al. (1997) A potassium-channel toxin from the sea anemone Bunodosoma granulifera, an inhibitor for Kv1 channels. Revision of the amino acid sequence, disulfide-bridge assignment, chemical synthesis, and biological activity. Eur J Biochem 244:192-202.
17. Deibler GE, Martenson RE, and Kies MW (1972) Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep Biochem 2:139-165.
18. + T cells in peripheral blood, synovial fluid and synovial tissue in patients with rheumatoid arthritis and osteoarthritis. Acta Med Okayama 51:25-31.
19. Felix JP, Bugianesi RM, Schmalhofer WA, Borris R, Goetz MA, Hensens OD, Bao JM, Kayser F, Parsons WH, Rupprecht K, et al. (1999) Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry 38:4922-4930.
20. Friedrich M, Krammig S, Henze M, Docke WD, Sterry W, and Asadullah K (2000) Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res 292:519-521.
21. Fujiwara Y, Akaji K, and Kiso Y (1994) Racemization-free synthesis of C-terminal cysteine-peptide using 2-chlorotrityl resin. Chem Pharm Bull (Tokyo) 42:724-726.
22. + channels from Leiurus quinquestriatus var. hebraeus venom. Biochemistry 33:6834-6839.
23. Ghanshani S, Wulff H, Miller MJ, Rohm H, Neben A, Gutman GA, Cahalan MD, and Chandy KG (2000) Up-regulation of the IKCa1 potassium channel during T-cell activation: molecular mechanism and functional consequences. J Biol Chem 275: 37137-37149.
24. Gradl SN, Felix JP, Isacoff EY, Garcia ML, and Trauner D (2003) Protein surface recognition by rational design: nanomolar ligands for potassium channels. J Am Chem Soc 125:12668-12669.
25. + channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol 45:1227-1234.
26. Gutman GA, Chandy KG, Adelman JP, Aiyar J, Bayliss DA, Clapham DE, Covarriubias M, Desir GV, Furuichi K, Ganetzky B, et al. (2003) International Union of Pharmacology. XLI. compendium of voltage-gated ion channels: potassium channels. Pharmacol Rev 55:583-586.
27. Hammerschmidt F and Hanbauer M (2000) Transformation of arylmethylamines into alpha-aminophosphonic acids via metalated phosphoramidates: rearrangements of partly configurationally stable N-phosphorylated alpha-aminocarbanions. J Org Chem 65:6121-6131.
28. Hanner M, Schmalhofer WA, Green B, Bordallo C, Liu J, Slaughter RS, Kaczorowski GJ, and Garcia ML (1999) Binding of correolide to Kv1 family potassium channels. J Biol Chem 274:25237-25244.
29. Hanson DC, Nguyen A, Mather RJ, Rauer H, Koch K, Burgess LE, Rizzi JP, Donovan CB, Bruns MJ, Canniff PC, et al. (1999) UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation. Br J Pharmacol 126:1707-1716.
30. Hendriks JJA, Alblas J, van der Pol SMA, van Tol EAF, Dijkstra CD, and de Vries HE (2004) Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. J Exp Med 200:1667-1672.
31. Iglesias A, Bauer J, Litzenburger T, Schubart A, and Linington C (2001) T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 36:220-234.
32. 22, a potent Kv1.3-specific immunosuppressive polypeptide. J Biol Chem 273:32697-32707.
33. King DS, Fields CG, and Fields GB (1990) A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. Int J Pept Protein Res 36:255-266.
34. + channels. Basis for high-affinity toxin interactions and pharmacology. J Biol Chem 272:27577-27581.
35. Ca channels. J Biol Chem 279:6893-6904.
36. Koo GC, Blake JT, Shah K, Staruch MJ, Dumont F, Wunderler D, Sanchez M, McManus OB, Sirotina-Meisher A, Fischer P, et al. (1999) Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell Immunol 197:99-107.
37. Koo GC, Blake JT, Talento A, Nguyen M, Lin S, Sirotina A, Shah K, Mulvany K, Hora D Jr, Cunningham P, et al. (1997) Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol 158:5120-5128.
38. Koschak A, Bugianesi RM, Mitterdorfer J, Kaczorowski GJ, Garcia ML, and Knaus HG (1998). Subunit composition of brain voltage-gated potassium channels determined by hongotoxin-1, a novel peptide derived from Centruroides limbatus venom. J Biol Chem. 273:2639-2644.
39. Lahey T and Rajadhyaksha VJ (2004) 3-Deoxyflavonoid inhibition of T-lymphocyte activation and therapeutic use, pp 19, US patent 2004102386.
40. Lin CS, Boltz RC, Blake JT, Nguyen M, Talento A, Fischer PA, Springer MS, Sigal NH, Slaughter RS, Garcia ML, et al. (1993) Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation. J Exp Med 177:637-645.
41. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, and Racke MK (1998) Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients: a marker of activated/memory T cells. J Clin Investig 101:725-730.
42. - costimulation-independent T cells in multiple sclerosis. J Clin Investig 108:1185-1194.
43. 22, reveals a novel pharmacological profile. Biochemistry 42:13698-13707.
44. + channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Biochem J 385:95-104.
45. 4I for the reduction of methionine sulphoxide in peptides containing cysteine and cystine. Tetrahedron 51:5701-5710.
46. O'Connor K, Bar-Or A, and Hafler DA (2001) The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol 21:81-92.
47. Pennington M, Byrnes M, Zaydenberg I, Khaytin I, de Chastonay J, Krafte D, Hill R, Mahnir V, Volberg W, Gorczyca W, et al. (1995) Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone. Int J Pept Protein Res 346:354-358.
48. Pennington M, Mahnir V, Khaytin I, Zaydenberg I, Byrnes M, and Kem W (1996a) An essential binding surface for ShK toxin interaction with rat brain potassium channels. Biochemistry 35:16407-16411.
49. Pennington M, Mahnir V, Krafte D, Zaydenberg I, Byrnes M, Khaytin I, Crowley K, and Kem W (1996b) Identification of three separate binding sites on ShK toxin, a potent inhibitor of voltage-dependent potassium channels in human T-lymphocytes and rat brain. Biochem Biophys Res Commun 219:696-701.
50. Peter MJ, Varga Z, Hajdu P, Gaspar RJ, Damjanovich S, Horjales E, Possani LD, and Panyi G (2001) Effects of toxins Pi2 and Pi3 on human T lymphocyte Kv1.3 channels: the role of Glu7 and Lys24. J Membr Biol 179:13-25.
51. + channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev 25:133-166.
52. Regaya I, Beeton C, Ferrat G, Andreotti N, Darbon H, De Waard M, and Sabatier JM (2004) Evidence for domain-specific recognition of SK and Kv channels by MTX and HsTX1 scorpion toxins. J Biol Chem 279:55690-55696.
53. Sallusto F, Lenig D, Forster R, Lipp M, and Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (Lond) 401:708-712.
54. Schmalhofer WA, Bao J, McManus OB, Green B, Matyskiela M, Wunderler D, Bugianesi RM, Felix JP, Hanner M, Linde-Arias AR, et al. (2002) Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties. Biochemistry 41:7781-7794.
55. Scholz C, Patton KT, Anderson DE, Freeman GJ, and Hafler DA (1998) Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 co-stimulation. J Immunol 160:1532-1538.
56. Singh S, Zink DL, Dombrowski AW, Dezeny G, Bills GF, Felix J, Slaughter RS, and Goetz MA (2001) Candelalides A-C: novel diterpenoid pyrones from fermentations of Sesquicillium candelabrum as blockers of the voltage-gated potassium channel Kv1.3. Org Lett 3:247-250.
57. Soler D, Humphreys TL, Spinola SM, and Campbell JJ (2003) CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood 101:1677-1682.
58. Task Force of the European Society of Cardiology the North American Society of Pacing Electrophysiology (1996) Heart Rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 93:1043-1065.
59. Tian Z, Gu C, Roeske RW, Zhou M, and Van Etten RL (1993) Synthesis of phosphotyrosine-containing peptides by solid-phase method. Int J Peptide Protein Res 42:155-158.
60. Valverde P, Kawai T, and Taubman M (2004) Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. J Bone Miner Res 19:155-164.
61. Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, Hansel W, and Chandy KG (2004) Kv1.3 blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol 65:1364-1374.
62. Viglietta V, Kent SC, Orban T, and Hafler DA (2002) GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Investig 109:895-903.
63. Wanner SG, Glossmann H, Knaus HG, Baker R, Parsons W, Rupprecht KM, Brochu R, Cohen CJ, Schmalhofer W, Smith M, et al. (1999) WIN 17317-3, a new high-affinity probe for voltage-gated sodium channels. Biochemistry 38:11137-11146.
64. Wernekenschnieder A, Korner P, and Hansel W (2004) 3-Alkyl- and 3-aryl-7H-furo[3,2-g]chromen-7-ones as blockers of the voltage-gated potassium channel Kv1.3. Pharmazie 59:319-320.
65. + channel in effector memory T cells as new target for MS. J Clin Investig 111:1703-1713.
66. + channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J Immunol 173:776-786.
67. + channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci USA 97:8151-8156.
68. + channels in microglia. J Gen Physiol 111:781-794.